Literature DB >> 16181231

Psychosocial morbidity of Graves' orbitopathy.

G J Kahaly1, F Petrak, J Hardt, S Pitz, U T Egle.   

Abstract

OBJECTIVE: Ocular diseases markedly impair daily function. In Graves' orbitopathy (GO), an associated psychosocial burden is present due to disfiguring proptosis and/or diplopia, signs with significant impact on functional status and well-being. We have therefore surveyed and assessed the psychosocial morbidity of GO.
DESIGN: A prospective controlled study on subjects with GO using internationally validated, self-reporting questionnaires. PATIENTS: One hundred and two consecutive patients with varying degrees of severity and activity of GO. Measurements Emotional distress, coping styles and quality of life (QoL) were assessed by the Hospital Anxiety and Depression Scale, by a German adaptation of the Ways-of-Coping Checklist, and with the 36-item Short Form, respectively. Stressful events in the 6 months preceding diagnosis were registered with the Life Experience Survey. QoL findings were compared to German reference values, as well as to 102 age- and gender-matched patients, each with type 1 diabetes (insulin-dependent diabetes mellitus, IDDM) and inflammatory bowel disease (IBD), respectively.
RESULTS: Compared to the German reference population, all QoL scales were at a lower rate and were especially decreased in subjects with active and/or severe GO, orbital pain, diplopia and stressful life events. Compared to diabetics, psychosocial scales were considerably reduced in GO (z = -1 vs. 0.1, P < 0.001) and higher scores for depressive coping (2.32 vs. 1.71, P < 0.001) and trivializing (2.37 vs. 1.97, P < 0.006) were noted. In GO, depressive coping and trivializing were negatively correlated with the mental (r = -0.603 and r =-0.411, both P < 0.001) and physical (r = -0.487 and r = -0.354, both P < 0.001) components of QoL. Depressive coping also positively correlated with anxiety (r = 0.636) and depression (r = 0.590), respectively, both P < 0.001. Emotional distress noted in 46 subjects, mostly with active and severe GO, was associated with poor QoL. Anxiety and depression were present in 41 and 24 GO patients, respectively. The number of stressful events positively correlated with the scores of anxiety (r = 0.3335) and depression (r = 0.3178), both P = 0.001. Foremost emotional distress, but also diplopia, stressful events and depressive coping had a major impact on QoL (proportion of variance explained = 13.1%, P < 0.001, multiple regression analysis). More than 75% of the psychosocial impairment in GO (R2= 0.76, P < 0.001) was associated with seven variables only (e.g. depression and anxiety). Six months prior to GO onset, 74 patients experienced a mean of 4 (range 0-13) stressful life events. Subjects with optic neuropathy had more stressful events than those without nerve involvement (5.1 vs. 2.7, P = 0.0425).
CONCLUSIONS: Psychosocial morbidity is present in severe and/or active GO, which negatively affects QoL. The patients are not only physically ill, they also exhibit emotional distress. Accompanying psychosomatic treatment is indicated among about half of all GO patients.

Entities:  

Mesh:

Year:  2005        PMID: 16181231     DOI: 10.1111/j.1365-2265.2005.02352.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  32 in total

1.  Currently available somatostatin analogs are not good for Graves' orbitopathy.

Authors:  M L Tanda; L Bartalena
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Measuring quality of life in oculoplastic patients.

Authors:  Edward Ridyard; Clare Inkster
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

Review 3.  [Graves' ophthalmopathy].

Authors:  A Eckstein; D Dekowski; D Führer-Sakel; U Berchner-Pfannschmidt; J Esser
Journal:  Ophthalmologe       Date:  2016-04       Impact factor: 1.059

Review 4.  Current and Emerging Treatment Strategies for Graves' Orbitopathy.

Authors:  Natalia Genere; Marius N Stan
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

5.  [Graves' ophthalmopathy from the internist's perspective].

Authors:  K Laubner; W A Weber; J Seufert
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

6.  Graves opthalmopathy and psychoendocrinopathies.

Authors:  Asaad A Ghanem; Mostafa A Amr; Lamiaa F Araafa
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

7.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

8.  [Endocrine ophthalmopathy. A visible psychophysical complaint].

Authors:  I Strempel
Journal:  Ophthalmologe       Date:  2016-02       Impact factor: 1.059

Review 9.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

10.  Quality of life and occupational disability in endocrine orbitopathy.

Authors:  Katharina A Ponto; Susanne Pitz; Norbert Pfeiffer; Gerhard Hommel; Matthias M Weber; George J Kahaly
Journal:  Dtsch Arztebl Int       Date:  2009-04-24       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.